Health Care Equipment

ZYLOXTB

Corebridge Technology repurchased 48,000 shares

Corebridge Life Sciences repurchased 28,500 shares on March 24

Guerbet Medical Technology Co., Ltd. reports significant revenue and net profit growth in 2025

ZYLOXTB released FY2025 9 Months Earnings on March 17 (BJT), actual revenue HKD 836.42 M, actual EPS HKD 0.6112

ZYLOXTB released FY2025 Q3 earnings on March 17, 2026 (BJT), with actual revenue of HKD 314.57 M and EPS of HKD 0.2105

ZYLOXTB released FY2025 Q4 earnings on March 17 After-Market (BJT), actual revenue HKD 320 M, actual EPS HKD 0.2142

ZYLOXTB released FY2025 Annual Earnings on March 17 After-Market (BJT), Actual Revenue HKD 1.156 B (Forecast HKD 1.182 B), Actual EPS HKD 0.8254 (Forecast HKD 0.6838)

ZYLOXTB to Release FY2025 Earnings on March 17 After-Market (BJT), Forecast Revenue HKD 1.19 B, EPS HKD 0.6885

GuiChuang TongQiao Medical Tech Expected Net Profit to Grow 139.4% to Over 240 Million RMB in 2025

GC Bridge Announces Acquisition of 49% Equity in Optimed Holding GmbH

Guotai Haitong Initiates Coverage with an Overweight Rating for MicroPort NeuroTech

GL Capital Management Increases Stake in Growtopia

GuiChuangTongQiao Reports 31.7% Revenue Growth in H1 2025, Strong Performance in Neurovascular Intervention Products

Corebridge Technology repurchased 50,000 shares on November 5, 2025

Coreflow Bridge repurchased 50,000 shares

Corebridge repurchased 50,000 shares

Corebridge Announces Grant of 13.95 Million Restricted Share Units

Conversana Bridge Repurchased 50,000 Shares for HKD 1.1844 Million

GuiChuangTongQiao repurchased 50,000 shares at a cost of about 1.253 million Hong Kong dollars

Guerbet Tong Bridge Repurchased 50,000 Shares for HKD 1,239,200

DATRONIX HOLD

PANGAEA CONNECT

HMVOD

EDICO HOLDINGS

MOMENTUM FIN

VPOWER GROUP

METASPACEX

EBROKER GROUP

CONGYU INTE AGR

UNITY ENT

02190

Zylox-Tonbridge Medical Technology Co., Ltd. has detailed the valuation basis for acquiring the remaining equity in a European vascular device maker, following an option to buy an additional 11% stake. This move aims to enhance its overseas vascular business and integrate with its sales network. The acquisition reflects the target's improving financials and anticipated growth in market coverage. Analysts rate the stock as a Buy with a target price of HK$28.00.

Tip Ranks

Zylox-Tonbridge Details Valuation Basis for Remaining Stake in Vascular Device Platform

Zylox-Tonbridge Medical Technology Co., Ltd. held its 2025 AGM on May 13, 2026, with 53.93% of voting share capital represented. All seven resolutions, including the board reports, financial statements, and profit distribution plan, were approved. Shareholders reappointed the external auditor for 2026 and authorized the board to set remuneration for directors. The latest analyst rating for the stock (HK:2190) is a Buy with a price target of HK$28.00. Zylox-Tonbridge focuses on developing medical devices and is listed on the Hong Kong Stock Exchange.

Zylox-Tonbridge Shareholders Approve All Proposals at 2025 AGM

Zylox-Tonbridge Medical Technology Co., Ltd. has granted 400,000 share options under its 2025 Share Incentive Scheme to an employee, with an exercise price of HK$23.472 per share. The options will vest by December 31, 2028, subject to performance conditions and a lock-up period. The company's stock (HK:2190) has a recent analyst rating of Buy with a price target of HK$28.00. Zylox-Tonbridge focuses on developing medical devices and has a market cap of HK$8.14B.

Zylox-Tonbridge Grants 400,000 Share Options Under 2025 Incentive Scheme

Zylox-Tonbridge Medical Technology Co., Ltd. reported its 2025 annual results, with revenue rising 35.1% year-over-year to RMB 1.06 billion and net profit increasing 143.7% to RMB 244 million. The growth was driven by strong performance in core products and international expansion. The company maintained a gross margin of 72.1% and proposed a final dividend of RMB 0.22 per share. Zylox-Tonbridge is focused on innovation and globalization, with a pipeline of 79 products and a strategic investment in Germany's Optimed Medizinische Instrumente GmbH to enhance its European presence.

prnewswire

12:18 ETZylox-Tonbridge Reports 2025 Annual Results with Revenue Exceeding RMB 1.06 Billion and Net Profit Up 143.7% Year-over-Year

ZYLOXTB announced its 2025 annual performance, with revenue of 1.057 billion RMB (the same below), an increase of 35.1% year-on-year; gross profit of 763 million RMB, up 36.3%. It recorded a net profit of 244 million RMB, a growth of 143.7%, with earnings per share of 76.46 cents. The final dividend declared is 22 cents, an increase of 12 cents

AASTOCKS

"Performance" ZYLOXTB's annual net profit of 244 million RMB increased by 143.7%, final dividend of 22 cents

Zylox-Tonbridge Profit Soars on Strong Neurovascular and Peripheral Device Growth in 2025

Zylox-Tonbridge Profit Soars on Strong Neurovascular and Peripheral Device Growth in 2025

ZYLOXTB(02190.HK)

Zylox-Tonbridge Details Valuation Basis for Remaining Stake in Vascular Device Platform

Zylox-Tonbridge Shareholders Approve All Proposals at 2025 AGM

Zylox-Tonbridge Grants 400,000 Share Options Under 2025 Incentive Scheme

12:18 ETZylox-Tonbridge Reports 2025 Annual Results with Revenue Exceeding RMB 1.06 Billion and Net Profit Up 143.7% Year-over-Year

"Performance" ZYLOXTB's annual net profit of 244 million RMB increased by 143.7%, final dividend of 22 cents

Zylox-Tonbridge Profit Soars on Strong Neurovascular and Peripheral Device Growth in 2025